Share: Facebook Twitter LinkedIn
Activity Provided By:

Evolve Medical Education LLC

Diabetic Eye Disease Pipeline Therapies Part 1: Faricimab, KSI-301, and OPT-302

Access Activity

Overview / Abstract:

This discussion with Program Chair Christina Y. Weng, MD, MBA, and David A Eichenbaum, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial.

Drs. Weng and Eichenbaum also converse about the latest data on pipeline therapies for diabetic macular edema, including faricimab, KSI-301, and OPT-302.

Expiration

Nov 30, 2022

Discipline(s)

Optometry / Ophthalmology CE

Format

Online, Webinar / Webcast / Video

Credits / Hours

0.5

Accreditation

ACCME

Keywords / Search Terms

Evolve Medical Education LLC Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map